EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Serum tumor necrosis factor levels and disease dissemination in leprosy and leishmaniasis



Serum tumor necrosis factor levels and disease dissemination in leprosy and leishmaniasis



Journal of Infectious Diseases 161(5): 988-991



It has been suggested that tumor necrosis factor alpha (TNF.alpha.) may serve as an important antigen-independent host defense mechanism against parasitic organisms. Sera from 66 patients with leishmaniasis and 68 patients with leprosy, all from Ethiopia, were tested for TNF.alpha. using an enzyme-linked immunoassay. Sera from patients with the multi-parasitic/bacillary type of disease (visceral or diffuse cutaneous leishmaniasis and lepromatous leprosy), known to be associated with absent or low specific T cell response, contained significantly higher TNF.alpha. titers than those of patients with pauci-parasitic/bacillary disease (localized cutaneous leishmaniasis and nonlepromatous leprosy). High titers of TNF.alpha. in the absence of a functioning T cell response do not appear to confer resistance against Leishmania aethiopica and Mycobacterium leprae.

(PDF same-day service: $19.90)

Accession: 002219879

Download citation: RISBibTeXText

PMID: 2324549

DOI: 10.1093/infdis/161.5.988



Related references

Serum levels of tumor necrosis factor in patients with American cutaneous leishmaniasis. Biological Research 26(1-2): 233-238, 1993

Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus. Clinical Biochemistry 38(2): 134-141, 2005

Serum tumor necrosis factor-alpha and soluble tumor necrosis factor receptor levels in hepatitis C virus infected patients A correlation with ALT levels. Gastroenterology 118(4 Suppl 2 Part 2): AASLD A143, April, 2000

Effects of interferon-alpha2a treatment on serum levels of tumor necrosis factor-alpha, tumor necrosis factor-alpha2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behcet's disease. Rheumatology International 19(1-2): 11-14, 1999

Effects of interferon-alpha2a treatment on serum levels of tumor necrosis factor-alpha, tumor necrosis factor-alpha2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behçet's disease. Rheumatology International 19(1-2): 11-14, 2000

Predictors of progression of liver disease in chronic hepatitis C patients with minimal fibrosis Kinetic of serum tumor necrosis factor and transforming growth factor serum levels. Journal of Hepatology 36(Supplement 1): 121, April, 2002

Serum levels of the apoptosis-associated molecules, tumor necrosis factor-alpha/tumor necrosis factor type-l receptor and Fas/FasL, in sepsis. Chest 125(6): 2238-2246, June, 2004

Interleukin 1 il 1 6il 6 and tumor necrosis factor tnf serum levels in crohns disease cd. Gastroenterology 100(5 PART 2): A576, 1991

Plasma levels of tumor necrosis factor-alpha in patients with visceral leishmaniasis (Kala-azar). Association with activity of the disease and clinical remission following antimonial therapy. Revista do Instituto de Medicina Tropical de Sao Paulo 38(2): 113-118, 1996

Increased serum levels of tumor necrosis factor receptor-associated factor 1 (TRAF1) correlate with disease activity and autoantibodies in rheumatoid arthritis. Clinica Chimica Acta; International Journal of Clinical Chemistry 462(): 103-106, 2016

Nutritional disturbances and serum levels of tumor necrosis factor tnf in crohns disease cd. Gastroenterology 100(5 PART 2): A242, 1991

Serum levels of tumor necrosis factor alpha and soluble tumor necrosis factor-receptor I in asthmatic patients and patients with chronic respiratory tract infection. Arerugi 46(11): 1136-1147, 1998